Soleno reported Q4 2025 product revenue, net, of USD 91.7 million and FY 2025 product revenue, net, of USD 190.4 million, reflecting sales of VYKAT XR (diazoxide choline) extended-release tablets following its U.S. approval on March 26, 2025 (the product had not been approved or commercially launched in the prior-year periods and therefore generated no revenue then). For Q4 2025, Soleno posted net income of USD 43.4 million and operating income of USD 39.6 million, with R&D expense of USD 9.6 million and SG&A expense of USD 40.9 million. For FY 2025, Soleno reported net income of USD 20.9 million and operating income of USD 9.4 million, with R&D expense of USD 40.6 million and SG&A expense of USD 132.1 million. On the commercial launch, from approval through Dec. 31, 2025 Soleno reported 1,250 patient start forms received (including 207 in Q4), 630 unique prescribers (including 136 new prescribers in Q4), 859 active patients on drug as of Dec. 31, 2025, and over 185 million lives covered. Soleno also said it invested USD 100.0 million in an accelerated share repurchase program and ended 2025 with USD 506.1 million of cash, cash equivalents and marketable securities, and noted it achieved profitability with FY net income of USD 20.9 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602251601PRIMZONEFULLFEED9661398) on February 25, 2026, and is solely responsible for the information contained therein.
Comments